Covered recipient · General Payments record
DENNIS M LACEY
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$2,962.04
91 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,950.25 | 86 |
| Travel and Lodging | $900.63 | 3 |
| Education | $111.16 | 2 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $1,536.08 | 14 |
| Biogen, Inc. | $242.21 | 13 |
| Kyowa Kirin, Inc. | $150.22 | 8 |
| ABBVIE INC. | $142.16 | 10 |
| Lundbeck LLC | $129.63 | 6 |
| Teva Pharmaceuticals USA, Inc. | $121.06 | 8 |
| UCB, Inc. | $108.67 | 5 |
| Lilly USA, LLC | $71.35 | 3 |
| Novartis Pharmaceuticals Corporation | $62.76 | 3 |
| Avion Pharmaceuticals | $59.10 | 3 |
| Biohaven Pharmaceutical Holding Company Ltd. | $48.15 | 3 |
| Corium, LLC | $41.60 | 2 |
| EMD Serono, Inc. | $39.59 | 2 |
| Grifols USA, LLC | $36.36 | 2 |
| Mylan Specialty L.P. | $24.94 | 1 |
| Supernus Pharmaceuticals, Inc. | $24.24 | 1 |
| EISAI INC. | $23.22 | 1 |
| ACADIA Pharmaceuticals Inc | $19.95 | 1 |
| Amgen Inc. | $19.82 | 1 |
| Acorda Therapeutics, Inc | $18.84 | 1 |
| Collegium Pharmaceutical, Inc. | $16.39 | 1 |
| Genentech USA, Inc. | $13.54 | 1 |
| IMPEL PHARMACEUTICALS INC. | $12.16 | 1 |
Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DENNIS M LACEY
NPI 1083696082 · CMS profile ID 230491
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
ATLANTA, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1083696082?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DENNIS M LACEY, NPI 1083696082, CMS profile ID 230491. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083696082?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). DENNIS M LACEY, NPI 1083696082, CMS profile ID 230491. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083696082?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- DENNIS M LACEY, NPI 1083696082, CMS profile ID 230491, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1083696082?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
91 matching records · $2,962.04 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–91 of 91.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| UCB, Inc. | $21.58 | 05/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908089184 | CMS |
| Kyowa Kirin, Inc. | $19.91 | 05/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 905043625 | CMS |
| ACADIA Pharmaceuticals Inc | $19.95 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 952386627 | CMS |
| Biogen, Inc. | $24.30 | 05/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923447933 | CMS |
| ABBVIE INC. | $9.74 | 05/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893124607 | CMS |
| Grifols USA, LLC | $15.58 | 04/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918669153 | CMS |
| Biogen, Inc. | $18.00 | 04/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923445245 | CMS |
| Novartis Pharmaceuticals Corporation | $18.36 | 04/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893867295 | CMS |
| Kyowa Kirin, Inc. | $19.85 | 04/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 905043615 | CMS |
| ABBVIE INC. | $7.91 | 04/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893124605 | CMS |
| Teva Pharmaceuticals USA, Inc. | $13.16 | 04/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954521080 | CMS |
| UCB, Inc. | $19.07 | 04/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908089177 | CMS |
| Biogen, Inc. | $19.24 | 04/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923437191 | CMS |
| Novartis Pharmaceuticals Corporation | $20.08 | 03/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893867291 | CMS |
| Genentech USA, Inc. | $13.54 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950789607 | CMS |
| Lilly USA, LLC | $25.35 | 03/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918001323 | CMS |
| Biogen, Inc. | $12.59 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923430545 | CMS |
| Avion Pharmaceuticals | $23.33 | 03/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 926515853 | CMS |
| UCB, Inc. | $21.06 | 03/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908089181 | CMS |
| ABBVIE INC. | $22.38 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893124603 | CMS |
| EMD Serono, Inc. | $12.26 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941500539 | CMS |
| Lundbeck LLC | $19.31 | 03/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945770551 | CMS |
| Mylan Specialty L.P. | $24.94 | 03/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963897947 | CMS |
| JAZZ PHARMACEUTICALS INC. | $20.12 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954284453 | CMS |
| JAZZ PHARMACEUTICALS INC. | $20.12 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954284455 | CMS |
| Acorda Therapeutics, Inc | $18.84 | 02/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920333515 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.89 | 02/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923646605 | CMS |
| IMPEL PHARMACEUTICALS INC. | $12.16 | 02/18/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 962311849 | CMS |
| ABBVIE INC. | $17.10 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893124601 | CMS |
| Biogen, Inc. | $17.83 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923415811 | CMS |
| UCB, Inc. | $24.93 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908089187 | CMS |
| ABBVIE INC. | $3.03 | 02/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893124599 | CMS |
| Lundbeck LLC | $18.47 | 02/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945770547 | CMS |
| Amgen Inc. | $19.82 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946544211 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.35 | 01/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923646603 | CMS |
| Novartis Pharmaceuticals Corporation | $24.32 | 01/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893867287 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.28 | 01/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954521039 | CMS |
| ABBVIE INC. | $15.34 | 01/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893124597 | CMS |
| Biogen, Inc. | $22.83 | 01/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923397155 | CMS |
| Kyowa Kirin, Inc. | $17.92 | 01/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 905043611 | CMS |
| Lundbeck LLC | $30.30 | 01/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945770543 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $540,513.70 | 223 |
| PY2024 | Recipient | $3,195.00 | 1 |
| PY2024 | Principal investigator | $954,682.55 | 188 |
| PY2023 | Principal investigator | $214,495.51 | 25 |
| PY2022 | Recipient | $20,313.00 | 2 |
| PY2022 | Principal investigator | $405,410.12 | 84 |
| PY2021 | Principal investigator | $290,845.28 | 44 |
| PY2020 | Principal investigator | $404,490.65 | 76 |
| PY2019 | Principal investigator | $15,372.12 | 15 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
223 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Alkermes, Inc. | $70.00 | 12/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624130 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,621.41 | 12/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223289664 |
| Principal investigator 1 | Alkermes, Inc. | $37.60 | 12/08/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615049 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,812.57 | 12/01/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223289001 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.65 | 11/24/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741220 |
| Principal investigator 1 | Alkermes, Inc. | $3,512.00 | 11/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617539 |
| Principal investigator 1 | Alkermes, Inc. | $806.00 | 11/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619915 |
| Principal investigator 1 | Alkermes, Inc. | $324.00 | 11/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621008 |
| Principal investigator 1 | Alkermes, Inc. | $400.00 | 11/10/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616063 |
| Principal investigator 1 | Alkermes, Inc. | $2,347.00 | 11/10/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618493 |
| Principal investigator 1 | Alkermes, Inc. | $2,347.00 | 11/10/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622073 |
| Principal investigator 1 | Alkermes, Inc. | $1.10 | 11/10/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624532 |
| Principal investigator 1 | Alkermes, Inc. | $650.00 | 10/27/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616285 |
| Principal investigator 1 | Alkermes, Inc. | $1,800.00 | 10/27/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617369 |
| Principal investigator 1 | Alkermes, Inc. | $1,500.00 | 10/27/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621222 |
| Principal investigator 1 | Alkermes, Inc. | $615.00 | 10/27/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626678 |
| Principal investigator 1 | Alkermes, Inc. | $3,500.00 | 10/15/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618489 |
| Principal investigator 1 | Alkermes, Inc. | $3,500.00 | 10/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617543 |
| Principal investigator 1 | Alkermes, Inc. | $126.00 | 10/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617989 |
| Principal investigator 1 | Alkermes, Inc. | $186.00 | 10/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626912 |
| Principal investigator 1 | Alkermes, Inc. | $2,800.00 | 09/08/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615747 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,400.00 | 09/04/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232946292 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $400.00 | 09/04/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232946296 |
| Principal investigator 1 | Alkermes, Inc. | $56.40 | 09/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616165 |
| Principal investigator 1 | Alkermes, Inc. | $150.00 | 09/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621742 |
| Principal investigator 1 | Alkermes, Inc. | $75.20 | 09/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622797 |
| Principal investigator 1 | Alkermes, Inc. | $172.25 | 09/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623952 |
| Principal investigator 1 | Alkermes, Inc. | $51.75 | 09/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623954 |
| Principal investigator 1 | Alkermes, Inc. | $71.60 | 09/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625956 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,827.98 | 08/21/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741218 |
| Principal investigator 1 | Alkermes, Inc. | $7,793.00 | 08/20/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623756 |
| Principal investigator 1 | Alkermes, Inc. | $70.00 | 08/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623914 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,712.49 | 08/08/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283983 |
| Principal investigator 1 | Alkermes, Inc. | $5,048.00 | 08/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614056 |
| Principal investigator 1 | Alkermes, Inc. | $7,281.00 | 08/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626818 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,390.00 | 08/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283857 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,049.00 | 08/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283859 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,016.00 | 08/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283861 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $973.00 | 08/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283863 |
| Principal investigator 1 | Alkermes, Inc. | $1,600.00 | 07/28/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616187 |
| Principal investigator 1 | Alkermes, Inc. | $2,800.00 | 07/28/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208624202 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,895.00 | 07/28/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741214 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $500.00 | 07/28/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741216 |
| Principal investigator 1 | Alkermes, Inc. | $1,200.00 | 07/11/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616613 |
| Principal investigator 1 | Alkermes, Inc. | $327.00 | 07/09/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624883 |
| Principal investigator 1 | Alkermes, Inc. | $800.00 | 07/02/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622817 |
| Principal investigator 1 | Alkermes, Inc. | $16.00 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613409 |
| Principal investigator 1 | Alkermes, Inc. | $127.40 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613611 |
| Principal investigator 1 | Alkermes, Inc. | $8.56 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614298 |
| Principal investigator 1 | Alkermes, Inc. | $32.70 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614489 |
| Principal investigator 1 | Alkermes, Inc. | $192.75 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614947 |
| Principal investigator 1 | Alkermes, Inc. | $115.65 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614951 |
| Principal investigator 1 | Alkermes, Inc. | $27.82 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615345 |
| Principal investigator 1 | Alkermes, Inc. | $162.05 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615683 |
| Principal investigator 1 | Alkermes, Inc. | $100.30 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615765 |
| Principal investigator 1 | Alkermes, Inc. | $93.50 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615921 |
| Principal investigator 1 | Alkermes, Inc. | $8.04 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615939 |
| Principal investigator 1 | Alkermes, Inc. | $50.15 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617067 |
| Principal investigator 1 | Alkermes, Inc. | $103.10 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617079 |
| Principal investigator 1 | Alkermes, Inc. | $5.95 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617665 |
| Principal investigator 1 | Alkermes, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617683 |
| Principal investigator 1 | Alkermes, Inc. | $25.70 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618141 |
| Principal investigator 1 | Alkermes, Inc. | $37.24 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618161 |
| Principal investigator 1 | Alkermes, Inc. | $8.56 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618167 |
| Principal investigator 1 | Alkermes, Inc. | $1.09 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618631 |
| Principal investigator 1 | Alkermes, Inc. | $36.40 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619321 |
| Principal investigator 1 | Alkermes, Inc. | $15.68 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619499 |
| Principal investigator 1 | Alkermes, Inc. | $4.28 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619601 |
| Principal investigator 1 | Alkermes, Inc. | $2.80 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619825 |
| Principal investigator 1 | Alkermes, Inc. | $103.10 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620083 |
| Principal investigator 1 | Alkermes, Inc. | $12.06 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620219 |
| Principal investigator 1 | Alkermes, Inc. | $38.55 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620273 |
| Principal investigator 1 | Alkermes, Inc. | $34.35 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620291 |
| Principal investigator 1 | Alkermes, Inc. | $2.80 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620938 |
| Principal investigator 1 | Alkermes, Inc. | $1.74 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621088 |
| Principal investigator 1 | Alkermes, Inc. | $25.70 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621138 |
| Principal investigator 1 | Alkermes, Inc. | $74.80 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621276 |
| Principal investigator 1 | Alkermes, Inc. | $1.05 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621780 |
| Principal investigator 1 | Alkermes, Inc. | $218.40 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622215 |
| Principal investigator 1 | Alkermes, Inc. | $16.08 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622573 |
| Principal investigator 1 | Alkermes, Inc. | $109.20 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622841 |
| Principal investigator 1 | Alkermes, Inc. | $74.24 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623342 |
| Principal investigator 1 | Alkermes, Inc. | $6.65 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624224 |
| Principal investigator 1 | Alkermes, Inc. | $21.40 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624250 |
| Principal investigator 1 | Alkermes, Inc. | $34.35 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624668 |
| Principal investigator 1 | Alkermes, Inc. | $51.55 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625117 |
| Principal investigator 1 | Alkermes, Inc. | $515.50 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625119 |
| Principal investigator 1 | Alkermes, Inc. | $9.35 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625237 |
| Principal investigator 1 | Alkermes, Inc. | $17.10 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625473 |
| Principal investigator 1 | Alkermes, Inc. | $8.04 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625517 |
| Principal investigator 1 | Alkermes, Inc. | $8.04 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626128 |
| Principal investigator 1 | Alkermes, Inc. | $33.32 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626210 |
| Principal investigator 1 | Alkermes, Inc. | $109.20 | 06/18/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626822 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/08/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613069 |
| Principal investigator 1 | Alkermes, Inc. | $19.41 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613812 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614002 |
| Principal investigator 1 | Alkermes, Inc. | $136.80 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618637 |
| Principal investigator 1 | Alkermes, Inc. | $220.78 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619751 |
| Principal investigator 1 | Alkermes, Inc. | $35.00 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620215 |
| Principal investigator 1 | Alkermes, Inc. | $341.02 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620443 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621090 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621494 |
| Principal investigator 1 | Alkermes, Inc. | $341.02 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624146 |
| Principal investigator 1 | Alkermes, Inc. | $135.00 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625247 |
| Principal investigator 1 | Alkermes, Inc. | $12.48 | 06/06/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626266 |
| Principal investigator 1 | Alkermes, Inc. | $2,369.00 | 06/04/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615379 |
| Principal investigator 1 | Alkermes, Inc. | $294.00 | 05/27/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617505 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 05/16/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618667 |
| Principal investigator 1 | Alkermes, Inc. | $756.00 | 05/16/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620313 |
| Principal investigator 1 | Alkermes, Inc. | $808.28 | 05/09/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626756 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $700.00 | 05/09/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223279334 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,958.49 | 05/09/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223279374 |
| Principal investigator 1 | Alkermes, Inc. | $2,400.00 | 05/07/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613641 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,700.00 | 05/07/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945360 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $8,100.00 | 05/07/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945364 |
| Principal investigator 1 | Alkermes, Inc. | $1,562.00 | 05/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616669 |
| Principal investigator 1 | Alkermes, Inc. | $327.00 | 05/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617937 |
| Principal investigator 1 | Alkermes, Inc. | $327.00 | 05/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619159 |
| Principal investigator 1 | Alkermes, Inc. | $2,293.00 | 05/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619647 |
| Principal investigator 1 | Alkermes, Inc. | $2,814.00 | 05/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623620 |
| Principal investigator 1 | Alkermes, Inc. | $327.00 | 05/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624294 |
| Principal investigator 1 | Alkermes, Inc. | $327.00 | 05/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625157 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 05/01/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615103 |
| Principal investigator 1 | Alkermes, Inc. | $2,032.00 | 04/23/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617203 |
| Principal investigator 1 | Alkermes, Inc. | $725.00 | 04/23/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619375 |
| Principal investigator 1 | Alkermes, Inc. | $7,793.00 | 04/23/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623470 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $1,400.00 | 04/23/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945223 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $1,000.00 | 04/23/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945227 |
| Principal investigator 1 | Alkermes, Inc. | $2,276.00 | 04/21/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613707 |
| Principal investigator 1 | Alkermes, Inc. | $1,045.00 | 04/21/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622994 |
| Principal investigator 1 | Alkermes, Inc. | $2,094.00 | 04/21/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623838 |
| Principal investigator 1 | Alkermes, Inc. | $1,200.00 | 04/14/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619687 |
| Principal investigator 1 | Alkermes, Inc. | $150.00 | 04/14/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621022 |
| Principal investigator 1 | Alkermes, Inc. | $147.00 | 04/14/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623658 |
| Principal investigator 1 | Alkermes, Inc. | $4,500.00 | 04/07/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613219 |
| Principal investigator 1 | Alkermes, Inc. | $300.00 | 04/07/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620764 |
| Principal investigator 1 | Alkermes, Inc. | $1,200.00 | 04/07/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621690 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $120.51 | 03/07/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223276145 |
| Principal investigator 1 | Alkermes, Inc. | $47.75 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613721 |
| Principal investigator 1 | Alkermes, Inc. | $35.20 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613956 |
| Principal investigator 1 | Alkermes, Inc. | $38.55 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616335 |
| Principal investigator 1 | Alkermes, Inc. | $259.54 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617161 |
| Principal investigator 1 | Alkermes, Inc. | $38.55 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618031 |
| Principal investigator 1 | Alkermes, Inc. | $119.36 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621040 |
| Principal investigator 1 | Alkermes, Inc. | $47.75 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621666 |
| Principal investigator 1 | Alkermes, Inc. | $56.85 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622103 |
| Principal investigator 1 | Alkermes, Inc. | $50.15 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623204 |
| Principal investigator 1 | Alkermes, Inc. | $8.80 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623206 |
| Principal investigator 1 | Alkermes, Inc. | $113.34 | 03/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623208 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,700.00 | 02/25/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232944856 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615359 |
| Principal investigator 1 | Alkermes, Inc. | $650.00 | 02/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616237 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619361 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619617 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621827 |
| Principal investigator 1 | Alkermes, Inc. | $650.00 | 02/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624500 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624696 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625866 |
| Principal investigator 1 | Alkermes, Inc. | $324.00 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613001 |
| Principal investigator 1 | Alkermes, Inc. | $167.05 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613293 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613723 |
| Principal investigator 1 | Alkermes, Inc. | $128.50 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615235 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616229 |
| Principal investigator 1 | Alkermes, Inc. | $89.95 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616297 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616321 |
| Principal investigator 1 | Alkermes, Inc. | $50.15 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616547 |
| Principal investigator 1 | Alkermes, Inc. | $47.75 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616959 |
| Principal investigator 1 | Alkermes, Inc. | $25.70 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617377 |
| Principal investigator 1 | Alkermes, Inc. | $25.70 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618941 |
| Principal investigator 1 | Alkermes, Inc. | $52.80 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619231 |
| Principal investigator 1 | Alkermes, Inc. | $162.05 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620389 |
| Principal investigator 1 | Alkermes, Inc. | $25.00 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621032 |
| Principal investigator 1 | Alkermes, Inc. | $0.85 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621038 |
| Principal investigator 1 | Alkermes, Inc. | $206.20 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621664 |
| Principal investigator 1 | Alkermes, Inc. | $6.40 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622095 |
| Principal investigator 1 | Alkermes, Inc. | $7.69 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623672 |
| Principal investigator 1 | Alkermes, Inc. | $100.30 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625680 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625682 |
| Principal investigator 1 | Alkermes, Inc. | $9.00 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626486 |
| Principal investigator 1 | Alkermes, Inc. | $412.40 | 02/12/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626710 |
| Principal investigator 1 | Alkermes, Inc. | $228.53 | 02/10/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623882 |
| Principal investigator 1 | Alkermes, Inc. | $82.08 | 02/10/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624352 |
| Principal investigator 1 | Alkermes, Inc. | $77.64 | 02/10/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624558 |
| Principal investigator 1 | Alkermes, Inc. | $52.48 | 02/10/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626712 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $750.00 | 02/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223274911 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,400.00 | 02/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223274913 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $750.00 | 02/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223274915 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $741.00 | 02/05/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223274917 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,797.92 | 02/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741202 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,268.88 | 02/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741204 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,268.88 | 02/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741206 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10,869.12 | 02/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741208 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,797.92 | 02/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741210 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,268.88 | 02/03/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233741212 |
| Principal investigator 1 | Eli Lilly and Company | $150.00 | 01/31/2025 | Non-covered Recipient Entity DR DENNIS M LACEY | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187879865 |
| Principal investigator 1 | Eli Lilly and Company | $570.00 | 01/31/2025 | Non-covered Recipient Entity DR DENNIS M LACEY | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187881146 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,500.00 | 01/29/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223274559 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $375.00 | 01/29/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223274561 |
| Principal investigator 1 | Alkermes, Inc. | $3,578.00 | 01/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616867 |
| Principal investigator 1 | Alkermes, Inc. | $1,347.00 | 01/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619133 |
| Principal investigator 1 | Alkermes, Inc. | $575.00 | 01/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619843 |
| Principal investigator 1 | Alkermes, Inc. | $2,616.00 | 01/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622227 |
| Principal investigator 1 | Alkermes, Inc. | $364.00 | 01/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624034 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,868.87 | 01/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223274413 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $800.00 | 01/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223274415 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $4,000.00 | 01/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232944602 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $1,500.00 | 01/22/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH INC | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232944606 |
| Principal investigator 1 | Eli Lilly and Company | $160,784.00 | 01/21/2025 | Non-covered Recipient Entity DR DENNIS M LACEY | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187881144 |
| Principal investigator 1 | Alkermes, Inc. | $1,914.00 | 01/17/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614993 |
| Principal investigator 1 | Alkermes, Inc. | $349.00 | 01/17/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616013 |
| Principal investigator 1 | Alkermes, Inc. | $349.00 | 01/17/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617923 |
| Principal investigator 1 | Alkermes, Inc. | $2,284.00 | 01/17/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620742 |
| Principal investigator 1 | Alkermes, Inc. | $806.00 | 01/17/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622643 |
| Principal investigator 1 | Alkermes, Inc. | $860.00 | 01/17/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623790 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 01/17/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625365 |
| Principal investigator 1 | Alkermes, Inc. | $324.00 | 01/17/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625597 |
| Principal investigator 1 | Alkermes, Inc. | $2,007.00 | 01/17/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625830 |
| Principal investigator 1 | Eli Lilly and Company | $734.77 | 01/14/2025 | Non-covered Recipient Entity DR DENNIS M LACEY | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187878867 |
| Principal investigator 1 | Eli Lilly and Company | $94,266.38 | 01/07/2025 | Non-covered Recipient Entity DR DENNIS M LACEY | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | No dispute reported | 06/30/2026 | 1187879967 |
| Principal investigator 1 | Eli Lilly and Company | $40,922.42 | 01/07/2025 | Non-covered Recipient Entity DR DENNIS M LACEY | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187879969 |
| Principal investigator 1 | Alkermes, Inc. | $15,156.91 | 01/01/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208627082 |
| Principal investigator 1 | Alkermes, Inc. | $10,678.47 | 01/01/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208627160 |
| Principal investigator 1 | Alkermes, Inc. | $16,536.51 | 01/01/2025 | Non-covered Recipient Entity NEUROTRIALS RESEARCH, INC. | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208627232 |